Commentary
Podcast
Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Author(s):
In Partnership With:
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Prothena Biosciences, we had the pleasure of speaking with Jack Khouri, MD, about the ongoing phase 3 AFFIRM-AL trial (NCT04973137) in amyloid light chain (AL) amyloidosis. Dr Khouri is an assistant professor of medicine at Case Western Reserve University School of Medicine and associate staff in the Department of Hematology and Medical Oncology at Cleveland Clinic in Ohio.
In our exclusive interview, Dr Khouri discussed unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab (Darzalex), and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial (NCT02312206) in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Prothena Biosciences. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
